Streetbeat News

Price Targets

CNM

Baird analyst David Manthey maintains an Outperform rating on Core & Main (NYSE:CNM) and raises the price target from $33 to $34.

Portfolio Pulse from jenniferd'souza@benzinga.com

June 07, 2023 | 11:06 am

THO

Baird analyst Craig Kennison maintains an Outperform rating on Thor Industries (NYSE:THO) and raises the price target from $95 to $110.

Portfolio Pulse from jenniferd'souza@benzinga.com

June 07, 2023 | 11:05 am

VRNT

Verint Systems Inc. (NASDAQ:VRNT) is expected to report lower Q1 earnings of 47 cents per share, down from 52 cents per share a year ago, with revenues of $216.15 million. Analysts have recently adjusted their price targets, with the most accurate analysts predicting an upside between 7% and 33%.

Portfolio Pulse from Lisa Levin

June 07, 2023 | 11:04 am

ASO

Baird analyst Justin Kleber maintains an Outperform rating on Academy Sports (NASDAQ:ASO) but lowers the price target from $75 to $70.

Portfolio Pulse from jenniferd'souza@benzinga.com

June 07, 2023 | 11:03 am

CIEN

Rosenblatt analyst Mike Genovese maintains a Buy rating on Ciena (NYSE:CIEN) but lowers the price target from $65 to $57.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 11:03 am

OESX

HC Wainwright & Co. analyst Amit Dayal reiterates a Buy rating on Orion Energy Sys (NASDAQ:OESX) and maintains a $7 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 11:02 am

RVNC

Mizuho analyst Vamil Divan maintains a Buy rating on Revance Therapeutics (NASDAQ:RVNC) and raises the price target from $33 to $35.

Portfolio Pulse from jenniferd'souza@benzinga.com

June 07, 2023 | 11:02 am

COIN

HC Wainwright & Co. analyst Mike Colonnese has reiterated a Buy rating on Coinbase Global (NASDAQ:COIN) and maintained a $77 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 11:01 am

PNW

Mizuho analyst Anthony Crowdell maintains a Neutral rating on Pinnacle West Capital (NYSE:PNW) and raises the price target from $74 to $80.

Portfolio Pulse from jenniferd'souza@benzinga.com

June 07, 2023 | 11:00 am

AGRX

HC Wainwright & Co. analyst Oren Livnat reiterated a Buy rating on Agile Therapeutics (NASDAQ:AGRX) and maintained a $12 price target.

Portfolio Pulse from richadhand@benzinga.com

June 07, 2023 | 11:00 am